.
() – , , ( .., .., 2009) ( .., 2013).
– , , , , - . , 125 . , 40%. , , , , , . , « » .
«» , , , - ( .., .., 2014). , , . , , - . , 24-52% ( ʸ). ( .., .., 2009).
, , . , , , . – - . ( .., 2013).
– (TNF-a) – . TNF-a – , , , , -, (IL-1, IL-6, IL-8, - ), , . TNF-a , , , , .
, . , , TNF-a, , , 1, 2, (-b). -1, -2, , – . TNF-a (DMARD) (, -) ( .., .., 2009).
7 47 %, 15% , «» 6-7 % , 73,2 % , . 50 % . , , , , , , , (?.., .., 2014).
( / / ), , 5 : 1 – (70%), 2 – (5%), 3 – (5%), 4 – (15%), 5 – (5%). 2006. – CASPAR (Classification criteria for soriatic Arthritis), – 98,7%, – 91,4%), , RF- (12% ) (39) ( .., .., 2009).
39. CASPAR (Classification criteria for soriatic Arthritis) (aylor W., 2006)
|
|
|
|
|
|
|
2 |
|
|
1 |
|
|
1 |
|
|
|
, , |
1 |
|
|
|
RF- ( -) |
1 |
|
|
|
|
1 |
|
|
1 |
|
|
|
( ) |
1 |
: , ,
? !
:


























:
:
:




